Understanding concentrated insulins: a systematic review of randomized controlled trials

Higher concentration insulins: an overview of clinical considerations

(2017) Timothy S. Reid et al.   POSTGRADUATE MEDICINE

New insulin preparations: A primer for the clinician

(2016) L. MENEGHINI   CLEVELAND CLINIC JOURNAL OF MEDICINE

Introduction

(2016)   DIABETES CARE

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)

(2016) M. Matsuhisa et al.   DIABETES OBESITY & METABOLISM

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)

(2016) Y. Terauchi et al.   DIABETES OBESITY & METABOLISM

Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension)

(2016) Munehide Matsuhisa et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes

(2016) Matthew C. Riddle et al.   Diabetes Technology & Therapeutics

EFFECT OF TOTAL DAILY DOSE ON EFFICACY, DOSING, AND SAFETY OF 2 DOSE TITRATION REGIMENS OF HUMAN REGULAR U-500 INSULIN IN SEVERELY INSULIN-RESISTANT PATIENTS WITH TYPE 2 DIABETES

(2016) Carol Wysham et al.   Endocrine Practice

Insulin

(2016) Alissa R. Segal et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance

(2016) David R. Owens   Expert Opinion on Drug Metabolism & Toxicology

Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial

(2016) Samaneh Kabul et al.   Health and Quality of Life Outcomes

A primer on concentrated insulins: what an internist should know

(2016) Adrienne Barnosky et al.   POSTGRADUATE MEDICINE

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)

(2015) Philip D. Home et al.   DIABETES CARE

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml

(2015) R. H. A. Becker et al.   DIABETES OBESITY & METABOLISM

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes

(2015) R. Ritzel et al.   DIABETES OBESITY & METABOLISM

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension

(2015) M. C. Riddle et al.   DIABETES OBESITY & METABOLISM

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extensi

(2015) H. Yki-Järvinen et al.   DIABETES OBESITY & METABOLISM

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)

(2015) G. B. Bolli et al.   DIABETES OBESITY & METABOLISM

Clinical use of insulin degludec

(2015) Jiten Vora et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

OPTIMIZED HUMAN REGULAR U-500 INSULIN TREATMENT IMPROVES β-CELL FUNCTION IN SEVERELY INSULIN-RESISTANT PATIENTS WITH LONG-STANDING TYPE 2 DIABETES AND HIGH INSULIN REQUIREMENTS

(2015) Andrea Mari et al.   Endocrine Practice

TWO TREATMENT APPROACHES FOR HUMAN REGULAR U-500 INSULIN IN PATIENTS WITH TYPE 2 DIABETES NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U-100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS: A RANDOMIZED, TITRATION-TO-TARGET CLINICAL TRIAL

(2015) Robert C. Hood et al.   Endocrine Practice

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

(2014) Matthew C. Riddle et al.   DIABETES CARE

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

(2014) Hannele Yki-Järvinen et al.   DIABETES CARE

Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes

(2014) M. Shiramoto et al.   DIABETES OBESITY & METABOLISM

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml

(2014) A. Steinstraesser et al.   DIABETES OBESITY & METABOLISM

Assessment of a New Insulin Preparation for Implanted Pumps Used in the Treatment of Type 1 Diabetes

(2014) Pauline Schaepelynck et al.   Diabetes Technology & Therapeutics

Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare)

(2014) Bruce Bode et al.   Endocrine Practice

Healthcare Costs and Adherence Associated with Human Regular U-500 Versus High-Dose U-100 Insulin in Patients with Diabetes

(2014) Elizabeth Eby et al.   Endocrine Practice

A 24-Week, Prospective, Randomized, Open-Label, Treat-To-Target Pilot Study of Obese Type 2 Diabetes Patients with Severe Insulin Resistance to Assess the Addition of Exenatide on the Efficacy of U-500 Regular Insulin Plus Metformin

(2014) Larry Distiller et al.   Endocrine Practice

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2013) David Moher   ANNALS OF INTERNAL MEDICINE

A Comparison of the Steady-State Pharmacokinetic and Pharmacodynamic Profiles of 100 and 200 U/mL Formulations of Ultra-Long-Acting Insulin Degludec

(2013) Stefan Korsatko et al.   CLINICAL DRUG INVESTIGATION

Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes

(2013) Stephen C.L. Gough et al.   DIABETES CARE

High-Dose Insulin Therapy: Is It Time for U-500 Insulin?

(2013) Wendy Lane et al.   Endocrine Practice

Insulin Stacking Versus Therapeutic Accumulation: Understanding the Differences

(2013) Tim Heise et al.   Endocrine Practice

Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials

(2013) Bernard Zinman et al.   Lancet Diabetes & Endocrinology

Insulin degludec: overview of a novel ultra long-acting basal insulin

(2012) S. C. L. Gough et al.   DIABETES OBESITY & METABOLISM

Humalog (lispro) for type 2 diabetes

(2012) Katherine Esposito et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Weight-Based, Insulin Dose–Related Hypoglycemia in Hospitalized Patients With Diabetes

(2011) Daniel J. Rubin et al.   DIABETES CARE

Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects

(2011) A. de la Pena et al.   DIABETES CARE

Use of concentrated insulin human regular (U-500) for patients with diabetes

(2010) A. R. Segal et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY